Cargando…

Middle East respiratory syndrome

Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease caused by a novel single-stranded, positive-sense RNA betacoronavirus (MERS-CoV). Dromedary camels, hosts for MERS-CoV, are implicated in direct or indirect transmission to human beings, although the exact mode of transmi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zumla, Alimuddin, Hui, David S, Perlman, Stanley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721578/
https://www.ncbi.nlm.nih.gov/pubmed/26049252
http://dx.doi.org/10.1016/S0140-6736(15)60454-8
_version_ 1782411243356684288
author Zumla, Alimuddin
Hui, David S
Perlman, Stanley
author_facet Zumla, Alimuddin
Hui, David S
Perlman, Stanley
author_sort Zumla, Alimuddin
collection PubMed
description Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease caused by a novel single-stranded, positive-sense RNA betacoronavirus (MERS-CoV). Dromedary camels, hosts for MERS-CoV, are implicated in direct or indirect transmission to human beings, although the exact mode of transmission is unknown. The virus was first isolated from a patient who died from a severe respiratory illness in June, 2012, in Jeddah, Saudi Arabia. As of May 31, 2015, 1180 laboratory-confirmed cases (483 deaths; 40% mortality) have been reported to WHO. Both community-acquired and hospital-acquired cases have been reported with little human-to-human transmission reported in the community. Although most cases of MERS have occurred in Saudi Arabia and the United Arab Emirates, cases have been reported in Europe, the USA, and Asia in people who travelled from the Middle East or their contacts. Clinical features of MERS range from asymptomatic or mild disease to acute respiratory distress syndrome and multiorgan failure resulting in death, especially in individuals with underlying comorbidities. No specific drug treatment exists for MERS and infection prevention and control measures are crucial to prevent spread in health-care facilities. MERS-CoV continues to be an endemic, low-level public health threat. However, the virus could mutate to have increased interhuman transmissibility, increasing its pandemic potential.
format Online
Article
Text
id pubmed-4721578
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-47215782016-01-21 Middle East respiratory syndrome Zumla, Alimuddin Hui, David S Perlman, Stanley Lancet Article Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease caused by a novel single-stranded, positive-sense RNA betacoronavirus (MERS-CoV). Dromedary camels, hosts for MERS-CoV, are implicated in direct or indirect transmission to human beings, although the exact mode of transmission is unknown. The virus was first isolated from a patient who died from a severe respiratory illness in June, 2012, in Jeddah, Saudi Arabia. As of May 31, 2015, 1180 laboratory-confirmed cases (483 deaths; 40% mortality) have been reported to WHO. Both community-acquired and hospital-acquired cases have been reported with little human-to-human transmission reported in the community. Although most cases of MERS have occurred in Saudi Arabia and the United Arab Emirates, cases have been reported in Europe, the USA, and Asia in people who travelled from the Middle East or their contacts. Clinical features of MERS range from asymptomatic or mild disease to acute respiratory distress syndrome and multiorgan failure resulting in death, especially in individuals with underlying comorbidities. No specific drug treatment exists for MERS and infection prevention and control measures are crucial to prevent spread in health-care facilities. MERS-CoV continues to be an endemic, low-level public health threat. However, the virus could mutate to have increased interhuman transmissibility, increasing its pandemic potential. Elsevier Ltd. 2015 2015-06-03 /pmc/articles/PMC4721578/ /pubmed/26049252 http://dx.doi.org/10.1016/S0140-6736(15)60454-8 Text en Copyright © 2015 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zumla, Alimuddin
Hui, David S
Perlman, Stanley
Middle East respiratory syndrome
title Middle East respiratory syndrome
title_full Middle East respiratory syndrome
title_fullStr Middle East respiratory syndrome
title_full_unstemmed Middle East respiratory syndrome
title_short Middle East respiratory syndrome
title_sort middle east respiratory syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721578/
https://www.ncbi.nlm.nih.gov/pubmed/26049252
http://dx.doi.org/10.1016/S0140-6736(15)60454-8
work_keys_str_mv AT zumlaalimuddin middleeastrespiratorysyndrome
AT huidavids middleeastrespiratorysyndrome
AT perlmanstanley middleeastrespiratorysyndrome